Advances in pancreatic cancer biomarkers

Syed Hasan, Rojymon Jacob, Upender Manne, Ravi Paluri

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


Biomarkers play an essential role in the management of patients with invasive cancers. Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced presentation and limited therapeutic options. This is further complicated by absence of validated screening and predictive biomarkers for early diagnosis and precision treatments respectively. There is emerging data on biomarkers in pancreatic cancer in past two decades. So far, the CA 19-9 remains the only approved biomarker for diagnosis and response assessment but limited by low sensitivity and specificity. In this article, we aim to review current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalOncology Reviews
Issue number1
StatePublished - 2019


  • Biomarkers
  • Pancreatic cancer


Dive into the research topics of 'Advances in pancreatic cancer biomarkers'. Together they form a unique fingerprint.

Cite this